Chemotherapy-naive patients with ED-SCLC were randomly assigned to receive IP , composed of irinotecan @ mg/m ( @ ) on days @ , @ , and @ and cisplatin @ mg/m ( @ ) on day @ every @ weeks , or AP , composed of amrubicin @ mg/m ( @ ) on days @ , @ , and @ and cisplatin @ mg/m ( @ ) on day @ every @ weeks .